Delays As Korea Grapples With Immuno-Oncology Drug Coverage
This article was originally published in PharmAsia News
With some of the new immuno-oncology drugs have already been launched in South Korea, experts are emphasizing the need to rapidly reimburse the innovative and pricey cancer therapies to reduce patients’ financial burden, amid debate over the best way of calculating prices.
You may also be interested in...
Amid repeated calls industry, South Korea decides to pay for Keytruda and Opdivo in its first reimbursement of immuno-oncology drugs, albeit at limited scope. The government is poised to expand reimbursement of IO drugs going forward amid its plan to significantly expand health insurance coverage.
South Korea's drug ministry, together with consumer and business groups, announces a raft of major regulatory innovation tasks it aims to achieve over the next few years, a major goal being to speed up patient access to innovation.
Plus deals involving Shionogi/ Grünenthal, CR Biopharma/ImmVira, Elevation Oncology/CSPC, Everest Medicines/TTY Biopharm and Dr. Reddy’s/Slayback